Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies

Cancer Research

Volumn 72, Issue 13, 2012, Pages 3163-3174

  Verbrugge, Inge ^a   Hagekyriakou, Jim ^a   Sharp, Leslie L ^c   Galli, Mara ^a   West, Alison ^a   McLaughlin, Nicole M ^a   Duret, Hél̀ene ^a   Yagita, Hideo ^d   Johnstone, Ricky W ^a,b   Smyth, Mark J ^a,b   Haynes, Nicole M ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PFIZER INC   (United States)

^d JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; GRANZYME B; IONOMYCIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD137; MONOCLONAL ANTIBODY CD40; MONOCLONAL ANTIBODY PD 1; PHORBOL 13 ACETATE 12 MYRISTATE; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; EX VIVO STUDY; INTERFERON PRODUCTION; IONIZING RADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; TRIPLE NEGATIVE BREAST CANCER; TUMOR REJECTION;

ANIMALS; ANTIBODIES; ANTIGENS, CD; CELL DEATH; IN SITU NICK-END LABELING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RADIATION, IONIZING; T-LYMPHOCYTE SUBSETS;

EID: 84863602592     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-0210     Document Type: Article

References (44)

1. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007;220:47-59. (Pubitemid 350045573)
2. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006;203:1259-71. (Pubitemid 43736595)
3. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718-26.
4. Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004;64:4328-37. (Pubitemid 38802440)
5. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005;11:3353-62. (Pubitemid 40627887)
6. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005;11:361-9. (Pubitemid 40075816)
7. Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, et al. Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer 2000;82:937-44. (Pubitemid 30085249)
8. Yokouchi H, Yamazaki K, Chamoto K, Kikuchi E, Shinagawa N, Oizumi S, et al. Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer. Cancer Sci 2008;99:361-7. (Pubitemid 351228493)
9. Shi W, Siemann DW. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res 2006;26:3445-53. (Pubitemid 44701521)
10. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009;15:5379-88.
11. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005;11:728-34. (Pubitemid 40116901)
12. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003;102:1449-57. (Pubitemid 36988056)
13. Shiao SL, Coussens LM. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010;15:411-21.
14. Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 2008;27:5894-903.
15. Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, Mittler RS, et al. Eradication of established tumors in mice by a combination antibodybased therapy. Nat Med 2006;12:693-8. (Pubitemid 43865240)
16. Christiansen AJ, West A, BanksKM, Haynes NM, TengMW,Smyth MJ, et al. Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad SciUS A 2011;108:4141-6.
17. Teng MW, Sharkey J, McLaughlin NM, Exley MA, Smyth MJ. CD1dbased combination therapy eradicates established tumors in mice. J Immunol 2009;183:1911-20.
18. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev Recent Clin Trials 2009;4:34-41.
19. Verbrugge I, Johnstone RW, Bots M. Promises and challenges of anticancer drugs that target the epigenome. Epigenomics 2011;3:547-65.
20. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010;107:4275-80.
21. Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti- ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A 2011;108:7142-7.
22. Tester AM, Ruangpanit N, Anderson RL, Thompson EW. MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelialmesenchymal transition traits. Clin Exp Metastasis 2000;18:553-60. (Pubitemid 32964317)
23. Stewart TJ, Abrams SI. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 2007;179:2851-9.
24. Mattarollo SR, Loi S, Duret H, Ma Y, Zitvogel L, Smyth MJ. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011;71:4809-20.
25. Verbrugge I, de Vries E, Tait SW, Wissink EH, Walczak H, Verheij M, et al. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. Oncogene 2008;27:574-84. (Pubitemid 351158906)
26. Verbrugge I, Wissink EH, Rooswinkel RW, Jongsma J, Beltraminelli N, Dupuis M, et al. Combining radiotherapy with APO010 in cancer treatment. Clin Cancer Res 2009;15:2031-8.
27. Haynes NM, Hawkins ED, Li M, McLaughlin NM, Hammerling GJ, Schwendener R, et al. CD11c+dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors. J Immunol 2010;185:532-41.
28. Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med 2004;199:437-48. (Pubitemid 38233828)
29. Yamazaki T, Akiba H, Koyanagi A, Azuma M, Yagita H, Okumura K. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol 2005;175:1586-92. (Pubitemid 41023060)
30. Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 2008;105:11317-22.
31. Solomon B, Hagekyriakou J, Trivett MK, Stacker SA, McArthur GA, Cullinane C. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 2003;55:713-23. (Pubitemid 36172491)
32. Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009;229:114-25.
33. Mujib S, Jones RB, Lo C, Aidarus N, Clayton K, Sakhdari A, et al. Antigen-independent induction of Tim-3 expression on human T cells by the common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 is associated with proliferation and is dependent on the phosphoinositide 3-kinase pathway. J Immunol 2012;188:3745-56.
34. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007;19:813-24. (Pubitemid 47241890)
35. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010;37:430-9.
36. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205:2763-79.
37. Dunn PL, North RJ. Selective radiation resistance of immunologically induced T cells as the basis for irradiation-induced T-cellmediated regression of immunogenic tumor. J Leukoc Biol 1991;49:388-96.
38. Schatten S, GransteinRD, Drebin JA,GreeneMI. Suppressor T cells and the immune response to tumors. Crit Rev Immunol 1984;4:335-79.
39. Enker WE, Jacobitz JL. In vivo splenic irradiation eradicates suppressor T-cells causing the regression and inhibition of established tumor. Int J Cancer 1980;25:819-25. (Pubitemid 10119824)
40. Kershaw MH, Jackson JT, Haynes NM, Teng MW, Moeller M, Hayakawa Y, et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 2004;173:2143-50. (Pubitemid 38971653)
41. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007;220:60-81. (Pubitemid 350045579)
42. Peter C, Wesselborg S, Herrmann M, Lauber K. Dangerous attraction: phagocyte recruitment and danger signals of apoptotic and necrotic cells. Apoptosis 2010;15:1007-28.
43. Gough MJ, Crittenden MR, Sarff M, Pang P, Seung SK, Vetto JT, et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother 2010;33:798-809.
44. Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, Penuelas I, et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011;71:801-11.